Neuroprotective effect of interleukin-6 in a rat model of cerebral ischemia

QILIN FENG¹, YI WANG¹ and YINGDA YANG²

¹Department of Pharmacy, Central Hospital of Wuhan; ²School of Pharmacy, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, P.R. China

Received May 25, 2014; Accepted March 4, 2015

DOI: 10.3892/etm.2015.2363

Abstract. Interleukin (IL)-6 is known to be a key cytokine in immune regulation in addition to serving crucial functions in various autoimmune diseases; however, the neuroprotective potential of IL-6 has not been fully investigated. The aim of the present study was to investigate the neuroprotective effects of the inflammatory cytokine IL-6 in a rat model of cerebral ischemia. Rat cerebral ischemia was induced by intraluminal middle cerebral artery occlusion. Following treatment with 500 or 50 ng IL-6, the infarct volumes and symptoms of neurological deficit were ameliorated. Furthermore, terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling staining suggested that the IL-6 treatment reduced neuronal apoptosis in vivo, which was consistent with a lower percentage of annexin V- and caspase-3-positive cortical neurons. In addition, IL-6 in vitro induced the phosphorylation of signal transducer and activator of transcription (STAT) 3 and the expression of induced myeloid leukemia cell differentiation protein Mcl-1, but not the expression of B-cell lymphoma 2, suggesting the activation of the Janus kinase/STAT pathway by IL-6. IL-6 also appeared to be involved in the regulation of cytokine secretion and blood-brain barrier (BBB) integrity in cerebral ischemia. IL-6 downregulated a number of inflammatory cytokines, including tumor necrosis factor-α and IL-1β, as well as myeloperoxidase activity, indicating the accumulation of granulocytes in the ischemic brain tissue. IL-6 was also observed to support the integrity of the BBB by reducing Evans blue leakage in vivo and suppressing the expression of matrix metalloproteinase-9 in ischemic brain tissue. In conclusion, the results of the present study indicate that the neuroprotective effects of IL-6 in cerebral ischemia are the result of a range of processes, including the modulation of cell apoptosis, cytokine secretion and the integrity of the BBB. IL-6 could therefore be used as a therapeutic agent in clinical practice.

Introduction

A previous study demonstrated that immune-related cytokines are involved in the pathology of cerebral ischemia and subsequent neuronal death (1); however, few cytokines, such as interleukin (IL)-1, nerve growth factor, transforming growth factor-β and tumor necrosis factor (TNF)-α, have been directly associated with cellular damage (2,3) following experimentally induced cerebral ischemia. IL-6 was initially identified as B-cell stimulating factor (4), and is also synthesized by neurons and glia. IL-6 mRNA expression in the brain is known to increase in various central nervous system (CNS) disorders, including cerebral ischemia (5,6). IL-6 has been demonstrated to be crucial for neuron survival in culture (7,8), and serves a key function in the regeneration of peripheral nerve cells (9,10).

IL-6 functions via two subunits of its receptor: The α-chain is the IL-6 binding protein gp80, and the β-chain is the signal-transducing protein gp130 (11). Two pathways are activated by gp130. The first pathway, the mitogen-activated protein kinase pathway, is Ras-dependent and leads to the activation of a variety of transcription factors, such as nuclear factor for IL-6, ETS domain-containing protein Elk-1 and activator protein 1; the second is the Janus kinase (JAK)-signal transducer and activator of transcription (STAT) pathway, which involves the activation of JAK and the STAT family members STAT1 and STAT3 (12,13). The two pathways have been implicated in cell proliferation and survival. Generally, the apoptosis-related B-cell lymphoma 2 (Bcl-2) protein family is believed to be a regulator of cell survival (14) and Bcl-2, which is highly expressed in malignant plasma cells, has been extensively studied among the Bcl-2 family proteins. Furthermore, a prior study has indicated that Bcl-2 protein is able to mediate cell cycle function (15). By contrast, Bcl-xL is thought to be a potential marker of chemoresistance regulating cell apoptosis in myeloma (16). A number of studies have indicated that induced myeloid leukemia cell differentiation protein Mcl-1 is crucial for the survival of B cells, particularly during the late stages of B-cell differentiation (17,18). In addition, IL-6 is known to regulate Mcl-1 and Bcl-xL proteins in myeloma cells (19,20). The aim of the present study, therefore,
is to investigate the neuroprotective effects of the inflammatory cytokine IL-6 in a rat model of cerebral ischemia, and to investigate the involvement of the JAK/STAT pathway, i.e. the phosphorylation of STAT3 following IL-6 treatment, in this process.

**Materials and methods**

**Rat models.** All experimental protocols were approved by the Institutional Animal Care and Use Committee of Tongji Medical College, Huazhong University of Science and Technology (Wuhan, China). Adult male Sprague Dawley rats weighing 250-280 g were obtained from Vital River Laboratory Animal Technology Co., Ltd. (Beijing, China). Focal cerebral ischemia was induced via intraluminal middle cerebral artery occlusion (MCAO), as described by Longa et al (21), with certain modifications. Briefly, the rats were intraperitoneally (i.p.) anesthetized with chloral hydrate (350 mg/kg), and a surgical nylon monofilament tip coated with 0.01% poly-L-lysine was then introduced into the left internal carotid artery through the external carotid stump. This filament was advanced 18-20 mm beyond the carotid bifurcation until a slight resistance was detected. At this point, the origin of the middle cerebral artery was obstructed by the intraluminal filament, and all blood flow from the internal carotid, anterior cerebral and posterior cerebral arteries was occluded. The body temperature of the rats was maintained at 37±0.5°C throughout the procedure. The filament was left in position for 2 h and then withdrawn. The rats were returned to their cages and closely monitored until they were observed to have recovered from the anesthesia. Any rats that exhibited an absence of neurological deficits immediately following reperfusion (neurological score, <3) were excluded from the study. Sham-operated rats were treated identically, with the exception that the MCAs were not occluded following the neck incision.

**Drug preparation and treatment schedule.** Recombined IL-6 was purchased from PeproTech, Inc. (Rocky Hill, NJ, USA) and dissolved in physiological saline. A total of 52 rats were divided at random into sham, saline, IL-6 (50 ng, i.p.) and IL-6 (500 ng, i.p.) treatment groups. IL-6 solution or a vehicle of physiological saline was administered 10 min after the MCAO procedure.

**Infarct volume determination.** Each rat was sacrificed 24 h after reperfusion and the brain was removed rapidly and frozen at -20°C for 5 min. Coronal slices were collected at points 2 mm from the frontal tips and immersed in 2% 2,3,5-triphenyltetrazolium chloride stain at 37°C for 20 min. Following staining, color images of the slices were captured using a Kodak 7230 digital camera (Kodak, Rochester, NY, USA) and Adobe Photoshop software, version 7.0 (Adobe Systems, Inc., San Jose, CA, USA). The infarct volume was calculated using the Mias-2000 image analysis system (Institute of Graphics and Images, Sichuan University, Chengdu, China).

**Neurological deficit determination.** Symptoms of neurological deficit in the vehicle- and drug-treated groups were assessed after 24 h of reperfusion according to the method described by Longa et al (21). Neurological findings were scored on a five-point scale, as follows: No neurological deficit, 0; failure to extend right paw fully, 1; circling to the right, 2; falling to the right, 3; and inability to walk spontaneously with depressed levels of consciousness, 4.

**Terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) staining.** To detect neuronal apoptosis, in situ nick end labeling was performed using a commercial kit (In Situ Apoptosis Detection kit; Roche Diagnostics, Indianapolis, IN, USA). Briefly, the tissue sections were washed in Tris-buffered saline (TBS) and permeabilized using Proteinase K (20 µg/ml) for 10 min. Following permeabilization, the sections were quenched for 5 min in 3% H2O2 in methanol at room temperature (RT). The sections were then incubated in equilibration buffer for 20 min prior to labeling for 100 min at 37°C. The reaction was terminated by stop buffer. Subsequent to further washing in TBS, the sections were incubated in peroxidase-streptavidin conjugate (In Situ Apoptosis Detection Kit) for 45 min, and reacted with 3,3'-diaminobenzidine tetrahydrochloride solution for 15 min at RT.

**Isolation of cortical neurons.** Cerebral cortices were isolated and the meninges removed, after which the tissue was minced and treated with 0.25% trypsin in Earle's balanced salt solution for 1 min. After centrifugation, cortical neurons were isolated. Neurons were isolated from each group, including the sham, saline, 50 ng IL-6 and 500 ng IL-6. Rats were treated with IL-6 (50 ng, i.p.) and IL-6 (500 ng, i.p.). IL-6 solution or a vehicle of physiological saline was administered 10 min after the MCAO procedure.

**Detection of annexin V staining and caspase-3 expression.** Cortical neurons, which were prepared and treated as described above, were double-labeled with phycoerythrin (PE)-conjugated caspase-3 monoclonal antibody and fluorescein isothiocyanate (FITC)-conjugated annexin V (BD Pharmingen, San Diego, CA, USA) for 1 h at RT. PE- and FITC-conjugated murine immunoglobulin G were used as controls. Subsequent to staining, the cells were assessed using flow cytometry. Cells were fixed and permeabilized, then 5x10^5 cells were stained with 1 µg/ml antibodies against the active form of caspase-3 and annexin V (BD-Pharmingen) for 60 min at room temperature. Cell were subsequently washed with phosphate-buffered saline and analyzed in a FACScan flow cytometer (FACSCalibur) and CellQuest software (BD Biosciences, Franklin Lakes, NJ, USA).

**Western blot analysis.** Protein expression and phosphorylation were detected by western blot analysis. After 12 h of culturing, the cells were lysed in buffer containing 125 mM Tris-HCl (pH 6.8), 20% glycerol, 1% 2-mercaptoethanol and 2% sodium dodecyl sulfate (SDS). The total protein from each sample was separated on a 12% SDS-polyacrylamide gel and electrophoresed onto a Hybond-C nitrocellulose membrane (Amersham Pharmacia, Freiburg, Germany). The membrane was subsequently blocked with 5% non-fat dry milk powder in TBS and incubated for 1 h with rat monoclonal phospho-Stat1 (#8826), Stat1 (#9139) and phospho-Stat3 (#9145) and polyclonal Stat1 (#9172) and Bcl2 (#2876) primary antibodies (1:1,000; Cell Systems, Inc., San Jose, CA, USA).
Signaling Technology, Inc., Danvers, MA, USA). In addition, a rat polyclonal McIl primary antibody (#A1832) from Selleck Chemicals was used (1:500, Shanghai, China). Following incubation, the membrane was washed four times with 0.05% Tween-20 in TBS and incubated with peroxidase-conjugated anti-rabbit (#7074) and anti-mouse (#7076) IgG secondary antibodies (Cell Signaling Technology, Inc.) for 1 h. The membrane was then washed extensively and the bands in the membrane were developed using enhanced chemiluminescence staining (Amersham Pharmacia).

**Measurement of myeloperoxidase (MPO) activity.** The enzymatic activity of MPO was measured as an indicator of the accumulation of granulocytes in the ischemic brain tissue (22). Briefly, the brains were rapidly removed at different time-points after MCAO (STAT1/3 and p-STAT1/3, 15 min; McI-1 and Bcl-2, 4 h). Samples of ischemic brain tissue weighing 100 mg were isolated, homogenized and centrifuged for 15 min at 12,000 x g (4˚C) for later biochemical analysis. An MPO activity assay was conducted using a commercial kit according to the manufacturer’s instructions (Nanjing Jiancheng Bioengineering Institute, Nanjing, China) (23). Alterations in the absorbance at 460 nm were measured using a spectrophotometer (GE Healthcare Bio-Sciences, Pittsburgh, PA, USA). One unit of MPO activity was defined as the degradation of 1 ml H2O2 per min at 37˚C. The final results were expressed as units of MPO activity per gram of wet brain tissue.

**Evans blue (EB) leakage.** Blood-brain barrier (BBB) permeability was detected by measuring the EB extravasation. EB leakage measurement was performed as described previously (24). The quantity of EB in the supernatant was measured spectrophotometrically at a wavelength of 610 nm and compared with readings obtained from standard solutions.

**Statistical analysis.** Quantitative data are presented as the mean ± standard deviation of at least three independent experiments. Histological injury scoring data were analyzed by analysis of variance (ANOVA) followed by the Kruskal-Wallis nonparametric test for comparison, which is presented as a box-and-whisker plot. The remaining data were analyzed by ANOVA and the Newman-Keuls test for comparison. For comparisons among the groups, the unpaired Student's t-test was performed using GraphPad Prism software (GraphPad Software, Inc., San Diego, CA, USA), in which P<0.05 was considered to indicate a statistically significant difference.

**Results**

**IL-6 treatment reduces infarct volume and neurological score.** To evaluate the efficacy of IL-6 in the rat model of cerebral ischemia/reperfusion, the infarct volume and neurological score were measured 24 h after the MCAO procedure. In the IL-6 treated rats, the infarct volume (Fig. 1A) and neurological score (Fig. 1B) were reduced significantly in a dose-dependent manner compared with those in the vehicle-treated rats. These results indicate that IL-6 is able to mitigate the damage associated with ischemia/reperfusion-induced brain injury.

**IL-6 treatment effectively inhibits ischemia-induced apoptosis.** To elucidate the mechanism underlying the neuroprotective effect of IL-6 on ischemia/reperfusion, neuronal apoptosis was determined using TUNEL staining. After 24 h of reperfusion, MCAO induced considerable DNA fragmentation and a large number of TUNEL-positive cells in the vehicle group compared with the sham group; however, the TUNEL-positive cell count was significantly reduced by the IL-6 treatment (Fig. 2A). To further confirm the effect of IL-6 on neuronal apoptosis, pure cortical neurons were isolated and the in vivo regulation of apoptosis by IL-6 injection was assessed. Consistently, 50 and 500 ng doses of IL-6 effectively inhibited the ischemia-induced apoptosis, as indicated by annexin V binding, compared with the vehicle control (Fig. 2B). In addition, the number of activated caspase-3-positive neurons also increased markedly in the vehicle group compared with the sham group (Fig. 2C), while IL-6 treatment attenuated this increase (Fig. 2C). These results indicate that IL-6 mitigates ischemia-induced neuronal apoptosis.

**IL-6 modulates neuronal anti-apoptotic proteins by activating STAT3 in the JAK/STAT pathway.** To further elucidate the

![Figure 1. Neuroprotective effect of IL-6 against cerebral ischemia. After 2 h middle cerebral artery occlusion and 24 h reperfusion, (A) infarct volume and (B) neurological score were measured in the vehicle (saline)- or IL-6 (50 or 500 ng)-treated and sham rats. Results are presented as the mean ± standard deviation and were assessed using one-way analysis of variance; *P<0.05, **P<0.01 and ***P<0.001 (n=8). IL-6, interleukin-6.](https://example.com/image.png)
mechanism underlying the inhibitory function of IL-6 on apoptosis, apoptotic proteins were examined using western blot analysis. To specifically investigate the JAK/STAT pathway, the cells were treated with various concentrations of IL-6 in vitro. As shown in Fig. 3A and B, IL-6 induced the phosphorylation of STAT3 while exerting no effect on total STAT3 expression. No difference was observed in the phosphorylation of STAT1 and total STAT1 expression following IL-6 treatment.
identical experimental conditions (Fig. 3A). Furthermore, neuronal Mcl-1 expression was upregulated following the IL-6 treatment (Fig. 3C), but the treatment did not result in any difference in Bcl-2 expression (Fig. 3D). These results suggest that IL-6 modulates neuronal anti-apoptotic proteins by activating STAT3 in the JAK/STAT pathway.

IL-6 treatment reduces levels of IL-1β and TNF-α and ameliorates EB leakage. The levels of a number of inflammatory cytokines were quantified in order to determine whether IL-6 influences the regulation of cytokine secretion and BBB integrity in cerebral ischemia. As shown in Fig. 4A and B, IL-6 induced a significant reduction in the levels of IL-1β and TNF-α in the rat brain, suggesting that IL-6 mediates the immune response following the inhibition of neuronal apoptosis. As inflammatory cytokines are responsible for the BBB integrity, the effect of IL-6 on the BBB permeability following ischemia-reperfusion was subsequently investigated. EB extravasation was detected in the ischemic region; however, IL-6 injection notably reduced this EB leakage in vivo (Fig. 4C). High levels of MMP-9 expression were observed in the ischemic brain tissue, and IL-6 reduced these levels (Fig. 4D). Furthermore, IL-6 reduced MPO activity in a dose-dependent manner (Fig. 4E).

Discussion

Apoptosis is a typical cell function with various characteristic morphological features, including DNA fragmentation, nuclear chromatin condensation and cell shrinkage. Apoptosis is widely implicated in neuronal disease; for example, apoptosis can lead to neuronal death in Alzheimer's disease, and amyloid β-protein may be involved in this process (25,26). It is, however, unknown which specific factors regulate the

![Figure 4. Effect of IL-6 on the central nervous system inflammatory response and blood-brain barrier permeability in rats following cerebral ischemic injury. (A-E) Effect of IL-6 on (A and B) the inflammatory IL-1β and TNF-α levels (determined by ELISA); (C) the EB content in rats brain following ischemia-reperfusion; (D) MMP-9 levels (determined by ELISA); and (E) the enzymatic activity of MPO. The ischemic brain was analyzed 24 h after middle cerebral artery occlusion. *P<0.05, **P<0.01 and ***P<0.001. IL, interleukin; TNF-α, tumor necrosis factor-α; EB, Evans blue; MMP-9, matrix metalloproteinase-9; MPO, myeloperoxidase.]

![Figure 5. Putative mechanism of IL-6 in cerebral ischemia. The effect of IL-6 on cerebral ischemia is attributed to the IL-6-mediated neuronal apoptosis decrease in vivo and in vitro. IL-6 regulates the apoptosis-related signaling in the neuron, inhibits the inflammatory cytokines in the brain and maintains the integrity of the BBB in the injured tissue, suggesting that IL-6 plays an important role in the therapy of cerebral ischemia-related neuronal diseases. IL-6, interleukin-6. BBB, blood-brain barrier.]

![Diagram of IL-6's role in cerebral ischemia]

IL-6 reduces non-apoptotic neuronal death by regulating Apaf-1 expression. The effect of IL-6 on neuronal death in cultured neurons was assessed by measuring Apaf-1 expression, a key player in the intrinsic apoptotic pathway. As shown in Fig. 5A, IL-6 treatment significantly reduced Apaf-1 expression in a dose-dependent manner (Fig. 5B). These results suggest that IL-6 modulates neuronal anti-apoptotic proteins by activating STAT3 in the JAK/STAT pathway.
apoptosis of neurons following cerebral ischemia. To confirm the anti-apoptosis effect of IL-6, the rate of neuronal apoptosis was measured using a number of independent methods in the present study. A TUNEL assay demonstrated that cerebral ischemia induced DNA fragmentation. Consistently, IL-6 also reduced annexin V binding and caspase-3 expression in freshly isolated cortical neurons compared with the cells from the saline-treated group. These results therefore demonstrate that IL-6 protects neurons against apoptosis. To elucidate the possible associated mechanism, the signal transduction was investigated in neurons from cerebral ischemia mice in vitro.

In the present study, high expression levels of Mcl-1 were observed to be associated with reduced levels of apoptosis in the IL-6-treated injured neurons. Mcl-1 is implicated in myeloid pathways upon exposure to 12-O-tetradecanoylphorbol-13-acetate (27). Although Mcl-1 has a key function in B-cell differentiation and survival, the exact role of Mcl-1 has not been defined (28,29). The results of the present study additionally reveal that IL-6 induces STAT3 phosphorylation in primary neuronal cells. We therefore hypothesized that the phosphorylation of STAT3 in the JAK/STAT pathway stimulates Mcl-1 expression. Consequently, these results suggest that STAT3 is involved in the IL-6-mediated anti-apoptosis activity, and the JAK/STAT pathway (30,31) may serve a key function in mediating Mcl-1 and the apoptotic processes.

The present study indicated that IL-6 is able to alleviate the cerebral ischemic/reperfusion damage in a rat model. Furthermore, IL-6 exerted a neuroprotective effect by inhibiting neuronal apoptosis and inflammatory mediators in the brain. Increased MPO activity was observed following the ischemic injury; however, IL-6 reduced the MPO activity, suggesting that IL-6 is able to inhibit the inflammatory responses in the brain. This observation was confirmed by the downregulation of inflammatory cytokines, including TNF-α and IL-1β. These results indicate that IL-6 ameliorates the symptoms of ischemic brain injury by preventing the secretion of inflammatory cytokines and the immune response in the brain. The breakdown of the BBB is involved in the pathogenesis of cerebral ischemia, and the present data regarding the reduced MMP-9 expression following IL-6 treatment are consistent with the reduction in EB content in the rat brain (32,33). This therefore suggests that IL-6 protects the BBB and exerts a neuroprotective effect in MCAO-induced cerebral ischemia. To the best of our knowledge, the present study is the first to demonstrate the efficacy of an inflammatory cytokine in a rat model of cerebral ischemia in rats via anti-inflammation and anti-apoptosis pathways (Fig. 5).

In conclusion, the results of the present study suggest that IL-6 plays a comprehensive role in cerebral ischemia by mediating neuronal apoptosis, inflammatory cytokines and BBB integrity in the CNS (Fig. 5). The present study has thus elucidated a possible mechanism underlying the actions of IL-6 in this disease and has indicated the possibility of the application of IL-6 as a therapeutic agent for cerebral ischemia.

Acknowledgements

The study was supported by a grant from the Natural Science Foundation of Hubei Province, China (no. 070413066).

References


27. Yang T, Buchan HL, Townsend KJ and Craig RW: MCL-1, a member of the BCL-2 family, is induced rapidly in response to signals for cell differentiation or death, but not to signals for cell proliferation. J Cell Physiol 166: 523-536, 1996.


